Company Profile

NGM Biopharmaceuticals Stock Price, News & Analysis

United StatesBiotechnologyNASDAQ

Company overview

Business overview

NGM Biopharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, NGM Biopharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.

Business Model Characteristics

NGM Biopharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.

Position Within the Biotechnology Landscape

Compared with more mature healthcare names, NGM Biopharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.

Why the stock is moving

NGM is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Future catalysts

NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.

Recent news

The five most recent feed items are shown below in reverse chronological order.

  1. 01
  2. 02

    NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

    Source: NGM Biopharmaceuticals

  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.